Neumora Therapeutics, Inc.

Originator Org.

Active Indication

Bipolar II disorder

Inactive Indication

Depressive Disorder [+1]

Drug Highest PhasePhase 2

First Approval Ctry. / Loc.-

First Approval Date-

NMRA-511

Target

AVPR1A

Mechanism

AVPR1A antagonists

Active Org.

Originator Org.

Active Indication

Agitation [+2]

Inactive Indication

Anxiety Disorders

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date-

NMRA-NMDA

Target

NMDA receptor

Mechanism

NMDA receptor modulators

Active Org.

Originator Org.

Active Indication

Schizophrenia

Inactive Indication-

Drug Highest PhasePreclinical

First Approval Ctry. / Loc.-

First Approval Date-

Clinical Trials associated with Neumora Therapeutics, Inc.

NCT06546995

/ RecruitingPhase 1

A Phase 1b, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.
Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.
Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment.
Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.

Start Date09 Jul 2024

Sponsor / Collaborator

NCT06429722

/ Active, not recruitingPhase 2

A Phase 2a, Randomized, Double-blind, Placebo-controlled Pilot Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With a Major Depressive Episode Associated With Bipolar II Disorder

This is a randomized, double-blind, placebo-controlled pilot study aiming to evaluate the effects of NMRA-335140 on symptoms of major depression in adults with Bipolar (BP) II disorder. The study design consists of a Screening Period (up to 28 days), a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo), and a 6-week Safety Follow-up Period.

Start Date13 May 2024

Sponsor / Collaborator

NCT06058039

/ RecruitingPhase 3

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder

This randomized, double-blind, placebo-controlled, multicenter study will evaluate the effects of NMRA-335140 (formerly BTRX-335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 35 days), and a 6-week Treatment Period (during which participants will receive either NMRA-335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an open-label extension study (NMRA-335140-501).

Start Date21 Dec 2023

Sponsor / Collaborator

Shareholders that lost money on Neumora Therapeutics, Inc.(NMRA) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

100 Clinical Results associated with Neumora Therapeutics, Inc.

0 Patents (Medical) associated with Neumora Therapeutics, Inc.

Literatures (Medical) associated with Neumora Therapeutics, Inc.

01 Oct 2024·Neuropharmacology

Navacaprant, a novel and selective kappa opioid receptor antagonist, has no agonist properties implicated in opioid-related abuse

Article

Author: Morrison, Filomene G ; Wallace, Tanya L ; Van Orden, Lori Jean ; Kuijer, Eloise J ; Zeitz, Karla ; Heal, David J ; Smith, Sharon L

Kappa opioid receptors (KORs) are implicated in the pathophysiology of various psychiatric and neurological disorders creating interest in targeting the KOR system for therapeutic purposes. Accordingly, navacaprant (NMRA-140) is a potent, selective KOR antagonist being evaluated as a treatment for major depressive disorder. In the present report, we have extended the pharmacological characterization of navacaprant by further demonstrating its selective KOR antagonist properties and confirming its lack of agonist activity at KORs and related targets involved in opioid-related abuse. Using CHO-K1 cells expressing human KOR, mu (MOR), or delta (DOR) opioid receptors, navacaprant demonstrated selective antagonist properties at KOR (IC₅₀ = 0.029 μM) versus MOR (IC₅₀ = 3.3 μM) and DOR (IC₅₀ > 10 μM) in vitro. In vivo, navacaprant (10-30 mg/kg, i.p.) dose-dependently abolished KOR-agonist induced analgesia in the mouse tail-flick assay. Additionally, navacaprant (10, 30 mg/kg, p.o.) significantly reduced KOR agonist-stimulated prolactin release in mice and rats, confirming KOR antagonism in vivo. Navacaprant showed no agonist activity at any opioid receptor subtype (EC₅₀ > 10 μM) in vitro and exhibited no analgesic effect in the tail-flick assays at doses ≤100 mg/kg, p.o. thereby confirming a lack of opioid receptor agonist activity in vivo. Importantly, navacaprant did not alter extracellular dopamine concentrations in the nucleus accumbens shell of freely-moving rats following doses ≤100 mg/kg, p.o., whereas morphine (10, 20 mg/kg, i.p.) significantly increased dopamine levels. These results demonstrate that navacaprant is a KOR-selective antagonist with no pharmacological properties implicated in opioid-related abuse.

09 Apr 2024·Neurology

Biological Staging of the Parkinson’s Progression Markers Initiative (PPMI) Cohort Using the Research Neuronal α-synuclein Disease Integrated Staging System (NSD-ISS) (P11-3.009)

Author: Chowdry, Sohini ; Stern, Matthew ; Brumm, Michael ; Nudelman, Kelly ; Kopil, Catherine ; Montine, Thomas ; Foroud, Tatiana ; Poewe, Werner ; Tolosa, Eduardo ; Xiao, Yuge ; Tanner, Caroline ; Coffey, Christopher ; Chahine, Lana ; Mollenhauer, Brit ; Poston, Kathleen ; Kieburtz, Karl ; Stephenson, Diane ; Simuni, Tanya ; DiBiaso, Peter ; Pagano, Gennaro ; Singleton, Andrew ; Concha-Marambio, Luis ; Marek, Kenneth ; Siderowf, Andrew ; Seibyl, John ; Frasier, Mark ; Weintraub, Daniel ; Jennings, Danna ; Soto, Claudio ; Gochanour, Caroline ; Sherer, Todd ; Merchant, Kalpana ; Dam, Tien

01 Jan 2023·RNA

SCRAP: a bioinformatic pipeline for the analysis of small chimeric RNA-seq data

Article

Author: Eadara, Sreenivas ; Jaffe, Andrew E ; Meffert, Mollie K ; Mills, William T

MicroRNAs (miRNAs) are small noncoding RNAs (sncRNAs) that function in post-transcriptional gene regulation through imperfect base pairing with mRNA targets, which results in inhibition of translation and typically destabilization of bound transcripts. Sequence-based algorithms historically used to predict miRNA targets face inherent challenges in reliably reflecting in vivo interactions. Recent strategies have directly profiled miRNA–target interactions by crosslinking and ligation of sncRNAs to their targets within the RNA-induced silencing complex (RISC), followed by high-throughput sequencing of the chimeric sncRNA:target RNAs. Despite the strength of these direct profiling approaches, standardized pipelines for effectively analyzing the resulting chimeric sncRNA:target RNA sequencing data are not readily available. Here we present SCRAP, a robustsmallchimeric RNAanalysispipeline for the bioinformatic processing of chimeric sncRNA:target RNA sequencing data. SCRAP consists of two parts, each of which is specifically optimized for the distinctive characteristics of chimeric small RNA sequencing reads: first, read processing and alignment and second, peak calling and annotation. We apply SCRAP to benchmark chimeric sncRNA:target RNA sequencing data sets generated by distinct molecular approaches, and compare SCRAP to existing chimeric RNA analysis pipelines. SCRAP has minimal hardware requirements, is cross-platform, and contains extensive annotations to broaden accessibility for processing small chimeric RNA sequencing data and enable insights into the targets of small noncoding RNAs in regulating diverse biological systems.

131

News (Medical) associated with Neumora Therapeutics, Inc.

13 Mar 2025

·www.prnewswire.com

NEW YORK, March 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CLASS PERIOD: This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023. ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora's flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. DEADLINE: April 7, 2025 Shareholders should not delay in registering for this class action. Register your information here: NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of NMRA during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is April 7, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT: The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-8903 SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

11 Mar 2025

·www.prnewswire.com

NASDAQ: NMRA Lawsuit Alert: Investors with substantial Losses from shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) should contact the Shareholders Foundation

SAN DIEGO, March 11, 2025 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA). Investors who purchased a significant number of shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) have certain options and there are short and strict deadlines running. Deadline: April 7, 2025. NASDAQ: NMRA investors should contact the Shareholders Foundation at [email protected] or call +1(858) 779 - 1554. On February 06 2025, an investor inNASDAQ: NMRA shares filed a lawsuit against Neumora Therapeutics, Inc. over alleged securities laws violations. The plaintiff claimed that the Offering Documents that were filed in connection with Neumora's September 2023 initial public offering contained false and/or misleading statements and/or failed to disclose that in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD, that and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD, and that the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study.. Those who purchased shares of Neumora Therapeutics, Inc. (NASDAQ: NMRA) should contact the Shareholders Foundation, Inc. CONTACT: Shareholders Foundation, Inc. Michael Daniels +1 (858) 779-1554 [email protected] 3111 Camino Del Rio North Suite 423 San Diego, CA 92108 The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. SOURCE Shareholders Foundation, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Clinical Result

07 Mar 2025

·www.prnewswire.com

Investors who lost money on Neumora Therapeutics, Inc.(NMRA) should contact Levi & Korsinsky about pending Class Action - NMRA

NEW YORK, March 7, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to the Offering Documents, commenced on or about September 15, 2023. Follow the link below to get more information and be contacted by a member of our team: NMRA investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500. CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder, MDD, to show that Navacaprant, Neumora's flagship therapeutic candidate, offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. WHAT'S NEXT? If you suffered a loss in Neumora Therapeutics, Inc. during the relevant time frame, you have until April 7, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate. WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. Ed Korsinsky, Esq. 33 Whitehall Street, 17th Floor New York, NY 10004 [email protected] Tel: (212) 363-7500 Fax: (212) 363-7171 SOURCE Levi & Korsinsky, LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2

100 Deals associated with Neumora Therapeutics, Inc.

100 Translational Medicine associated with Neumora Therapeutics, Inc.

Corporation Tree

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 04 Aug 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 1 Clinical

Phase 2 Clinical

Other

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Navacaprant ( κ opioid receptor )	Bipolar II disorder More	Phase 2
NMRA-511 ( AVPR1A )	Alzheimer Disease More	Phase 1
NMRA-M4R ( M4 receptor )	Nervous System Diseases More	Preclinical
NMRA-NMDA ( NMDA receptor )	Schizophrenia More	Preclinical
NMRA GCase ( GBA1 )	Parkinson Disease More	Preclinical

Deal

Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.